ImmuneOnco (1541) Gains Approval for Phase III Clinical Protocol Targeting Relapsed/Refractory Follicular Lymphoma

Bulletin Express11-27

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 1541) has obtained approval from the Center for Drug Evaluation of the National Medical Products Administration for a Phase III clinical study protocol of IMM0306 in combination with lenalidomide to treat relapsed/refractory follicular lymphoma. This development signals accelerated progress in seeking innovative therapies targeting this specific indication.

IMM0306, an internally developed bispecific molecule targeting CD47 and CD20, is positioned as the first of its kind to advance into the clinical stage worldwide. By inhibiting CD47-SIRPα interactions and enhancing macrophage and NK cell activation, the molecule aims to effectively eliminate malignant B cells while minimizing toxicity. ImmuneOnco holds global intellectual property and commercial rights to IMM0306.

According to the announcement, there are no guarantees on successful commercial development of IMM0306. Shareholders and potential investors are advised to exercise due care in handling related securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147916824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147916824","market":"hk","top_or_hot":-1,"title":"ImmuneOnco (1541) Gains Approval for Phase III Clinical Protocol Targeting Relapsed/Refractory Follicular Lymphoma","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 1541) has obtained approval from the Center for Drug Evaluation of the National Medical Products Administration for a Phase III clinical study protocol of IMM0306 in combination with lenalidomide to treat relapsed/refractory follicular lymphoma. This development signals accelerated progress in seeking innovative therapies targeting this specific indication.</p>\n<p>IMM0306, an internally developed bispecific molecule targeting CD47 and CD20, is positioned as the first of its kind to advance into the clinical stage worldwide. By inhibiting CD47-SIRPα interactions and enhancing macrophage and NK cell activation, the molecule aims to effectively eliminate malignant B cells while minimizing toxicity. ImmuneOnco holds global intellectual property and commercial rights to IMM0306.</p>\n<p>According to the announcement, there are no guarantees on successful commercial development of IMM0306. Shareholders and potential investors are advised to exercise due care in handling related securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco (1541) Gains Approval for Phase III Clinical Protocol Targeting Relapsed/Refractory Follicular Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco (1541) Gains Approval for Phase III Clinical Protocol Targeting Relapsed/Refractory Follicular Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-27 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 1541) has obtained approval from the Center for Drug Evaluation of the National Medical Products Administration for a Phase III clinical study protocol of IMM0306 in combination with lenalidomide to treat relapsed/refractory follicular lymphoma. This development signals accelerated progress in seeking innovative therapies targeting this specific indication.</p>\n<p>IMM0306, an internally developed bispecific molecule targeting CD47 and CD20, is positioned as the first of its kind to advance into the clinical stage worldwide. By inhibiting CD47-SIRPα interactions and enhancing macrophage and NK cell activation, the molecule aims to effectively eliminate malignant B cells while minimizing toxicity. ImmuneOnco holds global intellectual property and commercial rights to IMM0306.</p>\n<p>According to the announcement, there are no guarantees on successful commercial development of IMM0306. Shareholders and potential investors are advised to exercise due care in handling related securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1147916824","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147916824","pubTimestamp":1764217233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 1541) has obtained approval from the Center for Drug Evaluation of the National Medical Products Administration for a Phase III clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco（1541）针对复发/难治性滤泡性淋巴瘤的III期临床方案获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 1541) has obtained approval from the Center for Drug Evaluation of the National Medical Products Administration for a Phase III clinical study protocol of IMM0306 in combination with lenalidomide to treat relapsed/refractory follicular lymphoma. This development signals accelerated progress in seeking innovative therapies targeting this specific indication.\nIMM0306, an internally developed bispecific molecule targeting CD47 and CD20, is positioned as the first of its kind to advance into the clinical stage worldwide. By inhibiting CD47-SIRPα interactions and enhancing macrophage and NK cell activation, the molecule aims to effectively eliminate malignant B cells while minimizing toxicity. ImmuneOnco holds global intellectual property and commercial rights to IMM0306.\nAccording to the announcement, there are no guarantees on successful commercial development of IMM0306. Shareholders and potential investors are advised to exercise due care in handling related securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147916824","isCrawlerRequest":true}